A 2016 review by Love et al. concluded that BSO with tamoxifen is an effective therapy for ER+ premenopausal breast cancer, particularly in resource-limited settings, as one-third of annual new cases of breast cancer globally are now hormone receptor-positive tumors in premenopausal women from low- and middle-income countries [47]. Here, NR4A1 is linked to breast carcinoma.